Drug intelligence / Profile preview

DWJ1567

Development stage: Phase 1
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWJ1567 is a small molecule drug developed by Daewoong Pharmaceutical. It is currently in Phase 1 clinical trials, where it is being evaluated for its pharmacokinetics and safety in healthy adult volunteers. The specific mechanism of action, therapeutic area, and target indications have not been publicly disclosed as of June 2025. The drug is being compared to DWC202312 in ongoing studies[1][2].

Beyond the preview

Go deeper on DWJ1567.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWJ1567.

Explore the full profile